Bernstein analyst Eve Burstein lowered the firm’s price target on Illumina (ILMN) to $140 from $145 and keeps a Market Perform rating on the ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

Illumina, Inc. ILMN has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1 ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of ...

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition and innovation in the US.

Read Our Latest Stock Analysis on Illumina Illumina Trading Down 0.9 % Illumina stock opened at $143.12 on Wednesday. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The ...

How Illumina's Erin Imsand and her team helped ... about a project still in the concept stage-what would become the NovaSeq X. She was asked to help incorporate lyophilization (better known ...

A central focus for Illumina has been the transition to its NovaSeq X platform, which promises to reduce sequencing costs by approximately threefold. This transition, however, has not been without its ...